GLP-1 drugs, psilocybin mushrooms, and the case for sublingual psilocin

GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro may interfere with oral psilocybin mushrooms by slowing digestion and altering absorption. Because psilocybin is a prodrug that must convert into psilocin (4-HO-DMT), the conversion process is tied to the gut and liver after oral dosing. The piece suggests reports of delayed onset, blunted or unpredictable effects, abrupt drop-offs, and more “non-event” experiences for GLP-1 users. A proposed workaround is sublingual or buccal administration of psilocin, which is already active and can cross mucosal membranes more directly, potentially giving faster onset (often 10-20 minutes) and more consistent effects while avoiding first-pass metabolism and gut bottlenecks. The article also flags tradeoffs: psilocin is more chemically unstable than psilocybin and is more tightly scheduled in many jurisdictions, so harm reduction and experimental preparation methods (lozenges, tinctures, films, etc.) are discussed as emerging alternatives. It concludes with a caution for GLP-1 users and calls for more study on interactions between common medications and psychedelic dosing.